-

06:38:37 PM

IVVD Stock News

IVVD - Invivyd Inc

03/22/23 4:30 PM

Nasdaq : IVVD

covid-19

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

Research published online today in peer-reviewed journal Science Translational Medicine Analysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically meaningful protection can be achieved at low neutralizing antibody titers Work builds on vaccine studies

RHEA-AI

negative

03/16/23 7:00 AM

Nasdaq : IVVD

conferencesearnings

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m.

RHEA-AI

neutral

03/06/23 7:00 AM

Nasdaq : IVVD

covid-19

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

Company seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate development of VYD222 and its pipeline of other candidates VYD222 mAb candidate has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5 Invivyd maintains guidance

RHEA-AI

neutral

03/01/23 4:15 PM

Nasdaq : IVVD

Investors purchased NASDAQ: IVVD shares between November 29 and December 14, 2021, should contact the Shareholders Foundation in connection with the Lawsuit against Invivyd, Inc.

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in of Invivyd, Inc. (NASDAQ:IVVD) shares over alleged securities laws violations by Invivyd, Inc. f.k.a. Adagio Therapeutics, Inc. Investors, who purchased shares

RHEA-AI

very negative

02/28/23 7:00 AM

Nasdaq : IVVD

conferences

Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference

Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen’s

RHEA-AI

neutral

02/03/23 7:30 AM

Nasdaq : IVVD

Invivyd Announces Changes to Executive Team

Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided to

RHEA-AI

neutral

12/19/22 7:00 AM

Nasdaq : IVVD

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on

RHEA-AI

neutral

12/06/22 4:01 PM

Nasdaq : IVVD

management

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer,

RHEA-AI

neutral

11/17/22 7:00 AM

Nasdaq : IVVD

partnershipclinical trialcovid-19

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- - Population Health Partners to integrate best-in-class capabilities to drive speed and

RHEA-AI

neutral

11/10/22 4:01 PM

Nasdaq : IVVD

earnings

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10 th at 4:30 p.m. ET

RHEA-AI

neutral

IVVD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteadagiotx.com
Security nameInvivyd Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees69

About Invivyd Inc

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.